

A Multi-Center Evaluation of Restorative Eye Treatment and INhance With Trihex Technology to Improve Aesthetic Outcomes When Used Pre- and Post-Blepharoplasty

Wendy W. Lee, MD; Steven Fagien, MD, FACS; Jennifer Murdock, MD; Michaela Bell, BS, MBA; and Alan D. Widgerow, MBCh, MMed, FCS, FACS[®]

Aesthetic Surgery Journal Open Forum 2022, 1–5

© The Author(s) 2022. Published by Oxford University Press on behalf of The Aesthetic Society.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<https://creativecommons.org/licenses/by-nc/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com <https://doi.org/10.1093/asjof/ojac089> www.asjopenforum.com

OXFORD
UNIVERSITY PRESS

Abstract

Background: Restorative Eye Treatment with TriHex Technology (RET) is a topical eye product with peptides and botanicals that reduce the appearance of crow's feet, under-eye bags, and dark circles. INhance with TriHex Technology (IH) is a topical product that has been clinically proven to accelerate the clearance of bruises and aid in the reduction of swelling. TriHex Technology has been shown to regenerate collagen and elastin.

Objectives: Evaluate the use of RET compared to a bland moisturizer prior to blepharoplasty and the bilateral use of INhance postoperatively.


Methods: Blepharoplasty patients were randomized to use either RET or a bland moisturizer, twice daily, on the designated periocular skin for 4 weeks prior to the procedure. Postoperatively, participants applied IH bilaterally, at least 4 times a day, and returned for follow-up on Days 1 or 3, 7, and 14. The removed upper-eyelid skin (13 patients) underwent independent dermatopathological evaluation.

Results: Investigators noted no differences in peri-operative complications but observed faster improvement in swelling, bruising, discomfort on the treated side. 85% of participants had less edema and bruising on the RET pretreated side. Biopsy results revealed improved extracellular matrix appearance on the RET pretreated side. Participants agreed that IH alleviated their swelling and noted that their skin felt and appeared more hydrated.

Conclusions: A regimen designed for eyelid surgery employing a pretreatment product component and a post treatment product appear to have a positive impact on measured outcomes in blepharoplasty patients including effects on bruising, swelling and patient comfort.

Level of Evidence: 4

Editorial Decision date: December 9, 2022; online publish-ahead-of-print December 14, 2022.



Dr Lee is a professor of clinical ophthalmology and dermatology, Oculofacial Plastic & Reconstructive Surgery, Orbit and Oncology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL, USA. Dr Fagien is an oculoplastic surgeon, Aesthetic Eyelid Plastic Surgery, Boca Raton, FL, USA. Dr Murdock is an oculoplastic surgeon, Plastic Eye Surgery Associates, PLLC, Houston, TX, USA. Ms Bell is the director of clinical research,

Alastin Skincare, Inc., Carlsbad, CA, USA. Dr Widgerow is a plastic surgeon, Division Chief, Research, Center for Tissue Engineering, Plastic Surgery Department, University of California, Irvine, CA, USA.

Corresponding Author:

Dr Alan D. Widgerow, 9 Waterway Irvine, CA 92614, USA.

E-mail: alan.widgerow@galderma.com; Instagram: @alanwidgero

Oculoplastic surgery may be performed to correct a medical issue or for aesthetic purposes. Common postprocedure recovery includes bruising and swelling.

TriHex Technology is a unique combination of tripeptide, hexapeptide, and other active agents within a specified formulation that promote neocollagenesis and ne elastogenesis, which has been shown via histology.¹ Restorative Eye Treatment with TriHex Technology (RET) is a topical eye product with peptides and actives which has shown clinically, an overall improvement in periocular skin and a significant decrease in fine lines, under-eye hollowing, under-eye bags, and dark circles with participants noting a significant overall improvement in the appearance of the skin around the eyes.²

INhance with TriHex Technology is a topical product that has been clinically proven postprocedures to accelerate the clearance of bruises and aid in the reduction of swelling.³ This study aimed to determine the benefits of a topical eye product used on one side preprocedure compared to a bland moisturizer on the other side to determine differences within the skin, after 4 weeks of use. Postprocedure, a separate product was applied bilaterally to assess for efficacy in bruising, swelling, and patient satisfaction.

METHODS

Before initiation, this multi-center, randomized, blinded study was approved through Integ Review Institutional Review Board (Austin, TX). The study was conducted from November 2020 to July 2021. Eligible participants were men and women that were undergoing a blepharoplasty and willing to refrain from the use of additional treatments, procedures, or topicals on the face during the course of the study. Participants were excluded that had been using topical products in the procedural area within 1 month of participation, had a previous hypersensitivity to any of the actives in the study products, had recent excessive sun exposure, history of keloid or hypertrophic scars, and women that were pregnant, lactating, or planning on becoming pregnant.

Participants were randomized to apply RET (Alastin Skincare, Inc., Carlsbad, CA) and a bland moisturizer (Cetaphil Lotion, Galderma, Fort Worth, TX), twice daily, on the designated right or left periocular skin for 4 weeks prior to the procedure. All products were packaged in non-identifiable identical containers so the patient and the investigators were blind to the product being used. At surgery, the excised upper-eyelid skin was sent to an independent dermatopathologist for staining and evaluation. Postoperatively, participants applied INhance—IH (Alastin Skincare, Inc., Carlsbad, CA) immediately bilaterally to the periocular skin, at least 4 times a day, and returned for follow-up on Days 3, 7, and 14. At every visit,

standardized photography was performed and on Day 14 postop, the participants completed a questionnaire assessing the use of INhance. Written consent was provided, by which the patients agreed to the use and analysis of their data.

RESULTS

Eleven females and 2 two males with a mean age of 60 years completed the study. Age range was 41–93 years. Eight patients had a bilateral upper-eyelid blepharoplasty, 1 patient had a combined upper-eyelid blepharoplasty with external levator resection, and 4 patients had a bilateral upper and lower blepharoplasty. Investigators used 2% lidocaine with 1:100,000 epinephrine and no complications were reported in this series. Each investigator used their own standard postop care including the following: depending on clinical site and procedure: antibiotic ointment for 1 week, lubricant drops in the eyes as needed, antibiotics for 5 days, steroid dose pack, cold compresses for 1–2 days, head elevation, activity restriction, and avoidance of blood thinners for 1-week postop, and suture removal at 1-week postop. All patients returned for follow-up on Days 3, 7, and 14, with an average follow-up of 35 minutes for each patient.

Investigator Assessment and Photography

Investigators noted that there were no differences in intra-op or postop complications but observed a faster improvement in swelling and bruising on the side pretreated with RET. This was further evaluated through photography, as 85% of participants had less edema and bruising on the side that was pretreated with RET (Figure 1).

Post Procedure Investigator Observations With INhance Compared to Other Patients Not Using INhance With TriHex Technology

Site 1

Patients noticed less bruising/swelling and felt soothing from the application process.

Site 2

Investigators reported less bruising, the early bruises resolved much more quickly than in patients not using IH.

Site 3

Investigator noticed a mild improvement in bruising and swelling in patients who used IH. Comfort level is no




Figure 1. Typical results as reported by investigators. Each patient shown here underwent upper or upper and lower blepharoplasty (U/L Bleph). The side that received REST is designated as shown. All photos were taken at in first postoperative week. (A) A 56-year-old female patient who underwent U/L Bleph shown 1 day post-surgery; investigator reported markedly less bruising swelling on the REST side. (B) A 63-year-old male patient who underwent U Bleph shown 3 days post-surgery; investigator reported less swelling on the REST side. (C) A 56-year-old female patient who underwent U Bleph shown 1 day post-surgery, no difference reported. (D) A 56-year-old female patient who underwent U/L Bleph shown 7 days post-surgery; investigator reported slightly less bruising swelling on the REST side. (E) A 61-year-old female patient who underwent U Bleph shown 3 days post-surgery; investigator reported less bruising swelling on the REST side. (F) A 63-year-old female patient who underwent U/L Bleph shown 7 days post-surgery; investigator reported slightly less swelling on the REST side. (G) A 61-year-old female patient who underwent U Bleph shown 3 days post-surgery; investigator reported less bruising swelling on the REST side. (H) A 62-year-old female patient who underwent U Bleph shown 3 days post-surgery; investigator reported less bruising swelling on the REST side. REST, restorative eye treatment side.

different, as there is really no discomfort associated with upper-eyelid blepharoplasties.

Participant Questionnaire

Of the participants that experienced postop edema, 89% strongly agreed or agreed that IH alleviated their swelling. Of the participants that experienced postop ecchymosis, 91% strongly agreed or agreed, that IH alleviated their bruising and 91% of participants strongly agreed or agreed that their skin felt and appeared more hydrated. All the participants liked the way the product felt when applied.

Biopsies

Thirteen upper-eyelid specimens were collected within the study. On 1 side, REST was applied and on the other side, a bland moisturizer for up to 4 weeks presurgery. An independent dermatopathologist (Laboratory & Pathology Diagnostics, Naperville, IL) blinded to the treatment received before surgery, completed the analyses. Hematoxylin & Eosin; Herovici and Movat stains were performed and a dermatopathologist compared sides with particular reference to extracellular matrix (ECM) health, neocollagenesis and ne elastogenesis. In 13 of 15 cases (87%), the changes showed remarkable consistency—healthier ECM, younger and more plentiful collagen and elastin; 2 cases showed no difference (Table; Figure 2).

Safety

There were no reported adverse events.

DISCUSSION

This study aimed to determine whether topical pretreatment of the eyelids prior to a blepharoplasty procedure improved postoperative recovery. In addition, a postoperative treatment formulation was used to determine the impact on postoperative bruising, swelling, and discomfort. The use of a topical eye product used on one side preprocedure was compared to a bland moisturizer on the other side to determine differences within the skin quality and appearance and postblepharoplasty recovery, after 4 weeks of use.

This study demonstrates that this treatment appeared to have made a difference in 85% of patients undergoing blepharoplasty surgery. Qualitative and subjective analysis demonstrated reduced edema, swelling, less bruising, and less patient reported discomfort. The postoperative regimen used was identical on both sides so the differences noted were attributed to the pretreatment application. TriHex technology has been used extensively as pretreatment “preparation of the surgical canvas” in numerous clinical trials with improved outcomes demonstrated.^{4–7} The scientific premise which has been demonstrated with gene expression, biopsies, in vitro testing, and clinical trials demonstrate that the active agents within the formulation recycle the contents of the ECM promoting a renewal and replacement of the structural proteins (collagen and elastin), renewal of basal stem cells, and thickening of epidermal and barrier layers. This translates into improved cellular protein cross talk with the ECM, thus optimizing healing patient outcomes.^{8–11} The product used postoperatively has been developed to decrease swelling and bruising based on actives that improve macrophage function in relation to red blood cell phagocytosis.³

Table Summary of Histology Findings

Patient label	Improved dermal extracellular matrix	Healthier collagen deposition	Healthier Elastin deposition	Healthier Epidermis (rete pegs)
1. TEM	RET	RET	RET	RET
2. CM	RET	RET	RET	RET
3. GW	RET	RET	RET	RET
4. RP	ND	ND	RET	ND
5. WL	RET	RET	RET	RET
6. BC	RET	RET	RET	RET
7. 003L	RET	RET	RET	RET
8. 003M	ND	ND	ND	ND
9. 004F	RET	RET	RET	RET
10. 004L	RET	RET	RET	RET
11. 005F	RET	RET	RET	RET
12. 005L	RET	RET	ND	RET
13. 005M	RET	RET	RET	RET

ND, no difference; RET, restorative eye treatment.




Figure 2. Typical example of histology differences in the same patient: (A, B) Hematoxylin and Eosin (H/E) staining—healthier extracellular matrix (ECM) with new wavy, organized collagen fibers (rectangle) on (A) RET side. (C, D) Herovici stains showing significant mucopolysaccharides (MPS) and new collagen fibers in (C) papillary dermis (rectangle) RET side compared with (D). (E, F) Movat stain demonstrating dense layers of new elastin deposition in papillary dermis E (rectangle) compared with (F). RET, restorative eye treatment side.

Limitations in this study include a heterogenous group of surgical patients, one-third of whom underwent lower as well as upper blepharoplasty, the small number and a double product evaluation, all of which may conclusions more difficult. That noted the positive investigators' impressions, particularly relating to patients that were pretreated with active product suggest an advantage of hastened recovery

in this pretreated group of patients. In addition, biopsy outcomes provide an objective confirmation of the changes seen at a molecular level which provide good evidence for the clinical improvements reported. In this regard, the emphasis of this study and its analysis concern the concept of surgical preconditioning, an approach that is being adopted more and more in the surgical realm. This is a

differentiating feature that can contribute to the knowledge base of current literature.

CONCLUSIONS

In conclusion, a regimen designed for eyelid surgery employing a pretreatment product component and a post-treatment product appear to have a positive impact on measured outcomes in blepharoplasty patients including effects on bruising, swelling, and patient comfort.

Disclosures

Dr Widgerow is the chief scientific officer of Galderma (Lausanne, Switzerland). Dr Widgerow and Ms Bell are employees of Galderma, both were involved in collating data and paper writing. There was no involvement in the actual trial. The remaining authors declared no potential conflicts of interest with respect to the research, authorship, and publication of this article.

Funding

Funding for the study was provided by Alastin Skincare, Inc, (Carlsbad, CA), a Galderma Company.

REFERENCES

1. Widgerow AD, Fabi SG, Palestine RF, et al. Extracellular matrix modulation: optimizing skin care and rejuvenation procedures. *J Drugs Dermatol*. 2016;15(Supplement_4):S63-S71. PMID 27050707.
2. Reivitis A, Karimi K, Griffiths C, Banayan A. A single-center, pilot study evaluating a novel TriHex peptide- and botanical-containing eye treatment compared to baseline. *J Cosmet Dermatol*. 2018;17(3):467-470. doi: [10.1111/jocd.12542](https://doi.org/10.1111/jocd.12542)
3. Widgerow AD, Jacob C, Palm MD, Garruto JA, Bell M. Developing a topical adjunct to injectable procedures. *J Drugs Dermatol*. 2020;19(4):398-404. doi: [10.36849/JDD.2020.5016](https://doi.org/10.36849/JDD.2020.5016)
4. Casas LA, Bell M, Claytor B, Ziegler ME, Widgerow AD. An analysis of patient-reported recovery outcomes of topical tripeptide/hexapeptide formulations utilized in a prospective randomized double-blind split neck and body study. *Aesthet Surg J Open Forum*. 2021;3(1):ojaa052. doi: [10.1093/asjof/ojaa052](https://doi.org/10.1093/asjof/ojaa052)
5. Claytor B, Casas L, Ziegler M, Widgerow AD, Bell M. Evaluating the efficacy, tolerability, and outcomes of topical tripeptide/hexapeptide formulations before and after liposuction of the medial thighs. *Aesthet Surg J Open Forum*. 2020;3(1):ojaa055. doi: [10.1093/asjof/ojaa055](https://doi.org/10.1093/asjof/ojaa055)
6. Widgerow A, Moradi A, Poehler J. A double-blind randomized controlled trial evaluating the efficacy and tolerability of a topical body treatment in combination with cryolipolysis procedures. *J Drugs Dermatol*. 2019;18(4):342-348. PMID 31012562.
7. Vanaman Wilson MJ, Bolton J, Fabi SG. A randomized, single-blinded trial of a tripeptide/hexapeptide healing regimen following laser resurfacing of the face. *J Cosmet Dermatol*. 2017;16(2):217-222. doi: [10.1111/jocd.12339](https://doi.org/10.1111/jocd.12339)
8. Calame A, D Widgerow Alan. Histological changes associated with extracellular matrix-remodeling topical therapy. *Dermatol Case Rep*. 2017;2(2):126. doi: [10.35248/2684-124X.17.2.126](https://doi.org/10.35248/2684-124X.17.2.126)
9. Widgerow AD, Cohen SR, Fagien S. Preoperative skin conditioning: extracellular matrix clearance and skin bed preparation, a new paradigm. *Aesthetic Surg J*. 2019;39(Supplement_3):S103-S111. doi: [10.1093/asj/sjz022](https://doi.org/10.1093/asj/sjz022)
10. Widgerow AD, Ziegler ME, Casas LA. Topical skin treatment and its influence on surgical healing: review of literature and underlying physiology. *Aesthet Surg J Open Forum*. 2021;3(3):ojab029. doi: [10.1093/asjof/ojab029](https://doi.org/10.1093/asjof/ojab029)
11. Ziegler ME, Claytor B, Bell M, Casas L, Widgerow AD. Gene expression changes in the skin of patients undergoing medial thigh liposuction with pre-surgical and post-surgical application of topical products. *Aesthet Surg J Open Forum*. 2020; 2(3):ojaa033. doi: [10.1093/asjof/ojaa033](https://doi.org/10.1093/asjof/ojaa033)